In this article:

Illumina (ILMN) was Upgraded to a Hold Rating at Credit Suisse

In this article:
In this article:

Credit Suisse analyst Lorenzo Biasio upgraded Illumina (ILMNResearch Report) to Hold yesterday and set a price target of $340.00. The company’s shares closed last Wednesday at $330.19, close to its 52-week low of $306.66.

According to TipRanks.com, Biasio is a 4-star analyst with an average return of 7.5% and a 61.1% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Merck & Company, and Thermo Fisher.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $417.55 average price target, representing a 25.3% upside. In a report issued on February 15, UBS also maintained a Hold rating on the stock with a $350.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $526.00 and a one-year low of $306.66. Currently, Illumina has an average volume of 1.04M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company’s products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.

Read More on ILMN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed